Skip to content
International Academy for Clinical Hematology (IACH) Logo
  • About
    • Mission
    • Bylaws
    • Topics
    • Membership
    • Founders
    • Conflict of Interest Policy
    • Clinical Hematology International
    • IACH Supporters
    • Terms of Service
    • Contact
  • Meetings
    • Controversies in Multiple Myeloma (COMy)
    • Controversies in MDS and AML (COMydAL)
    • Controversies in Lymphoma (COLYM)
    • MPNControversies & Debates (MPN Co&D)
    • Annual Meeting of the IACH
    • Summit on Immunotherapy and Cellular Therapy in Cancer (ICTC)
  • Webinars
    • Webinars
    • Post-Cong. webinars
    • Special webinars
  • IACH for Nurses
  • Journal Club
  • Junior Club
  • IACH Special Events
    • IACH Giants
    • IACH CAR-T News
    • The Innovation and R&D Podium
  • IACH News (Podcasts)

Christopher Hourigan – How to distinguish to Acute Myeloid Leukemia from Non-Malignant Clonal Hematopoiesis?

  1. Home
  2. All
  3. Christopher Hourigan – How to distinguish to Acute Myeloid Leukemia from Non-Malignant Clonal Hematopoiesis?
Previous Next

Christopher Hourigan – How to distinguish to Acute Myeloid Leukemia from Non-Malignant Clonal Hematopoiesis?

By Amnon Ron|2021-09-09T14:49:42+00:00September 9th, 2021|All|Comments Off on Christopher Hourigan – How to distinguish to Acute Myeloid Leukemia from Non-Malignant Clonal Hematopoiesis?

Share This Story, Choose Your Platform!

FacebookTwitterRedditLinkedInWhatsAppTumblrPinterestVkEmail

About the Author: Amnon Ron

Related Posts

Dec 5th 2023- Prof. Wolfgang Bethge- Outcomes of Axicabtagene Ciloleucel in PMBCL Compare Favorably with those in DLBCL: a GLA/DRST Registry Study

Dec 5th 2023- Prof. Wolfgang Bethge- Outcomes of Axicabtagene Ciloleucel in PMBCL Compare Favorably with those in DLBCL: a GLA/DRST Registry Study

Nov 28th 2023- Prof. Ibrahim Yakoub-Agha- Nonrelapse Mortality After CAR T-cell Therapy for Large B-cell Lymphoma: a LYSA Study from the DESCAR-T Registry

Nov 28th 2023- Prof. Ibrahim Yakoub-Agha- Nonrelapse Mortality After CAR T-cell Therapy for Large B-cell Lymphoma: a LYSA Study from the DESCAR-T Registry

Nov 21st 2023- Prof. Moshe Mittelman- A Randomized Comparison of CPX-351 and FLAG-Ida in Adverse Karyotype AML and High-Risk MDS: The UK NCRI AML19 Trial

Nov 21st 2023- Prof. Moshe Mittelman- A Randomized Comparison of CPX-351 and FLAG-Ida in Adverse Karyotype AML and High-Risk MDS: The UK NCRI AML19 Trial

Nov 14th 2023- Dr. Bipin Savani- Vitamin C and D Supplementation in Acute Myeloid Leukemia

Nov 14th 2023- Dr. Bipin Savani- Vitamin C and D Supplementation in Acute Myeloid Leukemia

Nov 6th 2023- Prof. Attilio Olivieri- Incidence, Clinical Presentation, Risk Factors, Outcomes, and Biomarkers in De Novo Late Acute GVHD

Nov 6th 2023- Prof. Attilio Olivieri- Incidence, Clinical Presentation, Risk Factors, Outcomes, and Biomarkers in De Novo Late Acute GVHD

About

The IACH, founded by an international group of physicians whose focus is to promote good clinical practice in the field of clinical hematology, is registered in England (Number: 14200227) under the Companies Act 2006.

In collaboration with:

Contact

International Academy for Clinical Hematology (IACH)
35 Ballards Lane
London N3 1XW
United-Kingdom
info@clinical-hematology.org
+44 203 291 1603
IACH on Twitter
IACH on LinkedIn

Copyright © 2022 International Academy for Clinical Hematology | All Rights Reserved
Page load link
Go to Top